Hereditary Angioedema (HAE) is a rare genetic condition that involves recurrent attacks of severe swelling in various parts of the body. Although there is no existing cure for HAE, research is underway on an investigational medication option for adolescents and adults 12 years or older.
The KONFIDENT Study is a clinical research study of an oral on-demand treatment for adolescents and adults with HAE type I or type II. The purpose of the KONFIDENT Study is to understand the effects of an investigational oral medication called KVD900, that works by inhibiting plasma kallikrein, which reduces swelling and may help to relieve symptoms of an HAE attack. Doctors are studying 2 different doses to see which one may be best as a safe on-demand treatment for HAE attacks.